Please ensure Javascript is enabled for purposes of website accessibility

Altria Sets Up for a Game-Changing Year

By Dan Caplinger – Updated Apr 9, 2019 at 12:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Marlboro maker issued its first report since making two big strategic purchases to broaden its business.

It's been an interesting quarter for Altria Group (MO 0.92%). After having gone for years successfully defending its core cigarette business from the ongoing slide in customer demand, Altria made two bold moves to shore up its growth prospects. The $1.8 billion investment in marijuana producer Cronos Group (CRON -3.83%) got the most attention from cannabis investors, but the $13 billion it spent to acquire a minority stake in e-cigarette leader JUUL Labs was an even bigger play on making the most of opportunities in the alternative-products space.

Coming into Thursday's fourth-quarter financial report, Altria investors expected typically modest gains in sales and earnings. The tobacco giant's results were roughly in line with those expectations, but far more important were the comments that Altria executives made about the strategic moves and their impact on the company's long-term future.

Check out the latest Altria earnings call transcript.

Photo collage of several dozen pictures of various Altria businesses.

Image source: Altria Group.

The latest from Altria's core businesses

Altria's fourth-quarter results reflected the relatively low growth that the company's been able to achieve lately. Revenue net of excise tax was up just 1.5% to $4.79 billion, falling a bit short of the $4.81 billion that most of those following the stock were expecting to see. Adjusted net income climbed just over 2% to $1.79 billion, and that worked out to adjusted earnings of $0.85 per share, matching the consensus forecast among investors.

Altria's segments showed relatively stable performance compared to recent periods. The smokeable products segment saw a 1.9% rise in revenue net of excise tax, with adjusted operating company income also rising about 2%. Cigarette shipment volumes were down 4.4%, accelerating from their rate of decline in the third quarter, but higher pricing and reduced spending on promotional efforts helped to shield the unit's financial results from the full brunt of the volume decrease. However, market share continued to suffer, and for the first time in a long time, Altria's overall share fell below the 50% mark. Marlboro held up relatively strong, but a half-percentage-point drop in Altria's discount brand market share took the figure down 0.6 percentage points to 49.8%.

Altria's wine business was especially weak. Revenue dropped 11%, and adjusted operating company income got cut in half as shipment volumes were down fully 15% from year-earlier levels.

What's new at Altria?

CEO Howard Willard celebrated the company's balanced approach. "[Altria domestic cigarette subsidiary Philip Morris USA] stabilized Marlboro and strengthened our combustible business," Willard said, and "we also took proactive steps that we believe uniquely position us for long-term success. Altria enters 2019 with an evolved business platform that includes our strong core tobacco businesses and new strategic investments with tremendous potential for growth."

Altria is pushing ahead with those key strategic measures. On the Cronos investment, Altria said that it's optimistic that shareholders will approve the purchase at a vote in February, and it's working on filing an antitrust review application on the JUUL Labs acquisition shortly. From a financial perspective, Altria isn't forecasting any appreciable impact on earnings from Cronos or JUUL, but it is hopeful that the company will be able to move forward with plans to market the IQOS heated-tobacco system upon receiving approval from the U.S. Food and Drug Administration.

In terms of guidance, Altria was fairly consistent with what most of those following the tobacco giant had expected. Full-year 2019 adjusted earnings should be between $4.15 and $4.27 per share, up 4% to 7% from 2018 levels. It expects reduced dividends from its investment in Anheuser-Busch Inbev (BUD 2.79%), as well as higher interest expense from the debt associated with its acquisitions. Yet with projections that the overall domestic cigarette industry will suffer another 3.5% to 5% drop in volume in 2019, Altria seems fairly optimistic about its ability to keep doing what it's done to shore up its financial strength.

Altria shareholders seemed happy with the way things are going, and the stock rose 3% on Thursday following the morning announcement. With JUUL and Cronos in its stable of companies, Altria has shown its determination to keep growing, and it'll be interesting to see how those investments pan out over the long run.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Anheuser-Busch InBev NV. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altria Group Stock Quote
Altria Group
MO
$45.15 (0.92%) $0.41
Anheuser-Busch InBev NV Stock Quote
Anheuser-Busch InBev NV
BUD
$58.17 (2.79%) $1.58
Cronos Group Inc. Stock Quote
Cronos Group Inc.
CRON
$3.01 (-3.83%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.